Pawan Karanam, MDAssistant Professor AdjunctDownloadHi-Res PhotoCardsAppointmentsMedical Oncology and HematologyPrimaryContact Infopawan.karanam@yale.eduLearn moreabout Contact InfoAboutResearchNewsGet In TouchPawan KaranamAboutCopy LinkTitlesAssistant Professor AdjunctBiographyDr. Karanam completed his internal medicine residency at St. Vincent's Medical Center, and his Hematology/Oncology fellowship at Gundersen Health System.AppointmentsMedical Oncology and HematologyAssistant Professor AdjunctPrimaryOther Departments & OrganizationsInternal MedicineMedical Oncology & HematologyMedical Oncology and HematologyYale Cancer CenterEducation & TrainingMDOsmania Medical College (1990)ResearchCopy LinkClinical TrialsCurrent TrialsPhase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell LymphomaHIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsLymphomaA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck CancersHIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsHead and Neck CancersRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsLung CancerNovel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaHIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsMyelomaThe CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibHIC ID2000030282RoleSub InvestigatorPrimary Completion Date01/01/2028Recruiting ParticipantsBreast CancerSee All Current Clinical TrialsNewsCopy LinkNewsMay 01, 2019Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesSource: Hartford Business JournalRead moreabout Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesGet In TouchCopy LinkContactsEmailpawan.karanam@yale.edu
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell LymphomaHIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsLymphoma
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck CancersHIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsHead and Neck Cancers
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsLung Cancer
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaHIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/01/2025Recruiting ParticipantsMyeloma
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and TucatinibHIC ID2000030282RoleSub InvestigatorPrimary Completion Date01/01/2028Recruiting ParticipantsBreast Cancer
May 01, 2019Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care ServicesSource: Hartford Business JournalRead moreabout Excellence, Innovation and Integration: Saint Francis Hospital Expands Cancer Care Services